Sceptics about nootropics ("smart drugs") are unwitting victims of the so-called Panglossian paradigm of evolution. They believe that our cognitive architecture has been so fine-honed by natural selection that any tinkering with such a wonderfully all-adaptive suite of mechanisms is bound to do more harm than good. Certainly the notion that merely popping a pill could make you brighter sounds implausible. It sounds like the sort of journalistic excess that sits more comfortably in the pages of Fortean Times than any scholarly journal of repute.
Yet as Dean, Morgenthaler and Fowkes' (hereafter "DMF") book attests, the debunkers are wrong. On the one hand, numerous agents with anticholinergic properties are essentially dumb drugs. They impair memory, alertness, verbal facility and creative thought. Conversely, a variety of cholinergic drugs and nutrients, which form a large part of the smart-chemist's arsenal, can subtly but significantly enhance cognitive performance on a whole range of tests. This holds true for victims of Alzheimer's Disease, who suffer in particular from a progressive and disproportionate loss of cholinergic neurons. Yet, potentially at least, cognitive enhancers can aid non-demented people too. Members of the "normally" ageing population can benefit from an increased availability of acetylcholine, improved blood-flow to the brain, increased ATP production and enhanced oxygen and glucose uptake. Most recently, research with ampakines, modulators of neurotrophin-regulating AMPA-type glutamate receptors, suggests that designer nootropics will soon deliver sharper intellectual performance even to healthy young adults.
DMF provide updates from Smart Drugs (1) on piracetam, acetyl-l-carnitine, vasopressin, and several vitamin therapies. Smart Drugs II offers profiles of agents such as selegiline (l-deprenyl), melatonin, pregnenolone, DHEA and ondansetron (Zofran). There is also a provocative question-and-answer section; a discussion of product sources; and a guide to further reading.
So what's the catch? One problem, to which not all authorities on nootropics give enough emphasis, is the complex interplay between cognition and mood. Thus great care should be taken before tampering with the noradrenaline/acetylcholine axis. Thought-frenzied hypercholinergic states, for instance, are characteristic of one "noradrenergic" sub-type of depression. A predominance of forebrain cholinergic activity, frequently triggered by chronic uncontrolled stress, can lead to a reduced sensitivity to reward, an inability to sustain effort, and behavioural suppression.
This mood-modulating effect does make some sort of cruel genetic sense. Extreme intensity of reflective thought may function as an evolutionarily adaptive response when things go wrong. When they're going right, as in optimal states of "flow experience", we don't need to bother. Hence boosting cholinergic function, alone and in the absence of further pharmacologic intervention, can subdue mood. It can even induce depression in susceptible subjects. Likewise, beta-adrenergic antagonists (e.g. propranolol (Inderal)) can induce depression and fatigue. Conversely, "dumb-drug" anticholinergics may sometimes have mood-brightening - progressing to deliriant - effects. Indeed antimuscarinic agents acting in the nucleus accumbens may even induce a "mindless" euphoria.
Now it might seem axiomatic that helping everyone think more deeply is just what the doctor ordered. Yet our education system is already pervaded by an intellectual snobbery that exalts academic excellence over emotional well-being. In the modern era, examination rituals bordering on institutionalised child-abuse take a heavy toll on young lives. Depression and anxiety-disorders among young teens are endemic - and still rising. It's worth recalling that research laboratories routinely subject non-human animals to a regimen of "chronic mild uncontrolled stress" to induce depression in their captive animal population; investigators then test putative new antidepressants on the depressed animals to see if their despair can be experimentally reversed by patentable drugs. The "chronic mild stressors" that we standardly inflict on adolescent humans can have no less harmful effects on the mental health of captive school-students; but in this case, no organised effort is made to reverse it. Instead its victims often go on to self-medicate with ethyl alcohol, tobacco and street drugs. So arguably at least, the deformed and emotionally pre-literate minds churned out by our schools stand in need of safe, high-octane mood-brighteners more urgently than cognitive-tweakers. Memory-enhancers might be more worthwhile if we had more experiences worth remembering.
One possible solution to this dilemma involves taking a cholinergic agent such as piracetam (Nootropil) or aniracetam (Draganon, Ampamet) that also enhances dopamine function. Some researchers tentatively believe that the mesolimbic dopamine system acts as the final common pathway for pleasure in the brain. This hypothesis may well prove simplistic. There are certainly complications: it is not the neurotransmitter dopamine itself, but the post-synaptic metabolic cascades it triggers, that underlies motivated bliss. Other research suggests that it is the endogenous opioid system, and in particular activation of the mu opioid receptors, that mediates pure pleasure. Mesolimbic dopamine amplifies "incentive-motivation": "wanting" and "liking" may have different substrates, albeit intimately linked. Moreover there are mood-elevating memory-enhancers such as phosphodiesterase inhibitors (e.g. the selective PDE4 inhibitor rolipram) that act on different neural pathways - speeding and strengthening memory-formation by prolonging the availability of CREB. In any event, several of the most popular smart drugs discussed by DMF do indeed act on both the cholinergic and dopaminergic systems. In addition, agents like aniracetam and its analogs increase hippocampal glutaminergic activity. Hippocampal function is critical to memory - and mood. Thus newly developed ampakines, agents promoting long-term potentiation of AMPA-type glutamate receptors, are powerful memory-enhancers and future nootropics.
Another approach to enhancing mood and intellect alike involves swapping or combining a choline agonist with a different, primarily dopaminergic drug. Here admittedly there are methodological problems. The improved test score performances reported on so-called smart dopaminergics may have other explanations. Not all studies adequately exclude the confounding variables of increased alertness, sharper sensory acuity, greater motor activity or improved motivation - as distinct from any "pure" nootropic action. Yet the selective dopamine reuptake blocker amineptine (Survector) is both a mood-brightener and a possible smart-drug. Likewise selegiline, popularly known as l-deprenyl, has potentially life-enhancing properties. Selegiline is a selective, irreversible MAO-b inhibitor with antioxidant, immune-system-boosting and anti-neurodegenerative effects. It retards the metabolism not just of dopamine but also of phenylethylamine, a trace amine also found in chocolate and released when we're in love. Selegiline also stimulates the release of superoxide dismutase (SOD); SOD is a key enzyme which helps to quench damaging free-radicals. Taken consistently in low doses, selegiline extends the life-expectancy of rats by some 20%; enhances drive, libido and endurance; and independently improves cognitive performance in Alzheimer's pa
tients and in some healthy normals. It is used successfully to treat canine cognitive dysfunction syndrome (CDS) in dogs. In 2006, higher dose (i.e. less MAO-b selective) selegiline was licensed as the antidepressant EMSAM, a transdermal patch. Selegiline also protects the brain's dopamine cells from oxidative stress. The brain has only about 30-40 thousand dopaminergic neurons in all. It tends to lose perhaps 13% a decade in adult life. An eventual 70%-80% loss leads to the dopamine-deficiency disorder Parkinson's disease and frequently depression. Clearly anything that spares so precious a resource might prove a valuable tool for life-enrichment.
In 2005, a second selective MAO-b inhibitor, rasagiline (Azilect) gained an EC product license. Its introduction was followed a year later in the USA. Unlike selegiline, rasagiline doesn't have amphetamine trace metabolites - a distinct if modest therapeutic advantage.
Looking further ahead, the bifunctional cholinesterase inhibitor and MAO-b inhibitor ladostigil acts both as a cognitive enhancer and a mood brightener. Ladostigil has neuroprotective and potential antiaging properties too. Its product-license is several years away at best.
Consider, for instance, the plight of genetically engineered "smart mice" endowed with an extra copy of the NR2B subtype of NMDA receptor. It is now known that such brainy "Doogie" mice suffer from a chronically increased sensitivity to pain. Memory-enhancing drugs and potential gene-therapies targeting the same receptor subtype might cause equally disturbing side-effects in humans. Conversely, NMDA antagonists like the dissociative anaesthetic drug ketamine exert amnestic, antidepressant and analgesic effects in humans and non-humans alike.
Amplified memory can itself be a mixed blessing. Even among the drug-nave and chronically forgetful, all kinds of embarrassing, intrusive and traumatic memories may haunt our lives. Such memories sometimes persist for months, years or even decades afterwards. Unpleasant memories can sour the well-being even of people who don't suffer from clinical PTSD. The effects of using all-round memory enhancers might do something worse than merely fill our heads with clutter. Such agents could etch traumatic experiences more indelibly into our memories. Or worse, such all-round enhancers might promote the involuntary recall of our nastiest memories with truly nightmarish intensity.
By contrast, the design of chemical tools that empower us selectively to forget unpleasant memories may prove to be at least as life-enriching as agents that help us remember more effectively. Unlike the software of digital computers, human memories can't be specifically deleted to order. But this design-limitation may soon be overcome. The synthesis of enhanced versions of protease inhibitors such as anisomycin may enable us selectively to erase horrible memories. If such agents can be refined for our personal medicine cabinets, then we'll potentially be able to rid ourselves of nasty or unwanted memories at will - as distinct from drowning our sorrows with alcohol or indiscriminately dulling our wits with tranquillisers. In future, the twin availability of 1] technologies to amplify desirable memories, and 2] selective amnestics to extinguish undesirable memories, promises to improve our quality of life far more dramatically than use of today's lame smart drugs.
Such a utopian pharmaceutical toolkit is still some way off. Given our current primitive state of knowledge, it's hard to boost the function of one neurotransmitter signalling system or receptor sub-type without eliciting compensatory and often unwanted responses from others. Life's successful, dopamine-driven go-getters, for instance, whether naturally propelled or otherwise, may be highly productive individuals. Yet they are rarely warm, relaxed and socially empathetic. This is because, crudely, dopamine overdrive tends to impair "civilising serotonin" function. Unfortunately, tests of putative smart drugs typically reflect an impoverished and culture-bound conception of intelligence. Indeed today's "high IQ" alpha males may strike posterity as more akin to idiot savants than imposing intellectual giants. IQ tests, and all conventional scholastic examinations, neglect creative and practical intelligence. They simply ignore social cognition. Social intelligence, and its cognate notion of "emotional IQ", isn't some second-rate substitute for people who can't do IQ tests. On the contrary, according to the Machiavellian ape hypothesis, the evolution of human intelligence has been driven by our superior "mind-reading" skills. Higher-order intentionality [e.g. "you believe that I hope that she thinks that I want...", etc] is central to the lives of advanced social beings. The unique development of human mind is an adaptation to social problem-solving and the selective advantages it brings. Yet pharmaceuticals that enhance our capacity for empathy, enrich our social skills, expand our "state-space" of experience, or deepen our introspective self-knowledge are not conventional candidates for smart drugs. For such faculties don't reflect our traditional [male] scientific value-judgements on what qualifies as "intelligence". Thus in academia, for instance, competitive dominance behaviour among "alpha" male human primates often masquerades as the pursuit of scholarship. Emotional literacy is certainly harder to quantify scientifically than mathematical puzzle-solving ability or performance in verbal memory-tests. But to misquote Robert McNamara, we need to stop making what is measurable important, and find ways to make the important measurable. By some criteria, contemporary IQ tests are better measures of high-grade autism than mature intelligence. So before chemically manipulating one's mind, it's worth critically examining which capacities one wants to enhance; and to what end?
In practice, the first and most boring advice is often the most important. Many potential users of smart pills would be better and more simply advised to stop taking tranquillisers, sleeping tablets or toxic recreational drugs; eat omega-3 rich foods, more vegetables and generally improve their diet; and try more mentally challenging tasks. One of the easiest ways of improving memory, for instance, is to increase the flow of oxygenated blood to the brain. This can be achieved by running, swimming, dancing, brisk walking, and more sex. Regular vigorous exercise also promotes nerve cell growth in the hippocampus. Hippocampal brain cell growth potentially enhances mood, memory and cognitive vitality alike. Intellectuals are prone to echo J.S. Mill: "Better to be an unhappy Socrates than a happy pig". But happiness is typically good for the hippocampus; by contrast, the reduced hippocampal volume anatomically characteristic of depressives correlates with the length of their depression.
In our current state of ignorance, homely remedies are still sometimes best. Thus moderate consumption of adenosine-inhibiting, common-or-garden caffeine improves concentration, mood and alertness; enhances acetylcholine release in the hippocampus; and statistically reduces the risk of suicide. Regular coffee drinking induces competitive and reversible inhibition of MAO enzymes type A and B owing to coffee's neuroactive beta-carbolines. Coffee is also rich in antioxidants. Non-coffee drinkers are around three times more likely to contract Parkinson's disease. A Michigan study found caffeine use was correlated with enhanced male virility in later life.
Before resorting to pills, aspiri
ng intellectual heavyweights might do well to start the day with a low-fat/high carbohydrate breakfast: muesli rather than tasty well-buttered croissants. This will enhance memory, energy and blood glucose levels. An omega-3 rich diet will enhance all-round emotional and intellectual health too. A large greasy fry-up, on the other hand, can easily leave one feeling muddle-headed, drowsy and lethargic. If one wants to stay sharp, and to blunt the normal mid-afternoon dip, then eating big fatty lunches isn't a good idea either. Fat releases cholecystokinin (CCK) from the duodenum. Modest intravenous infusions of CCK make one demonstrably dopey and subdued.
To urge such caveats is not to throw up one's hands in defeatist resignation. Creative psychopharmacology can often in principle circumvent such problems, even today. Complementary and sometimes effective combinations such as sustained-release methylphenidate (Ritalin) and SSRIs such as fluoxetine (Prozac), for instance, are arguably still under-used. They could be more widely applied both in clinical psychiatry and, at least in the context of a general harm-reduction strategy, on the street. There may indeed be no safe drugs but just safe dosages. Yet some smart drugs, such as piracetam, really do seem to be at worst pretty innocuous. Agents such as the alpha-1 adrenergic agonist adrafinil (Olmifron) typically do have both mood-brightening and intellectually invigorating effects. Adrafinil, like its chemical cousin modafinil (Provigil), promotes alertness, vigilance and mental focus; and its more-or-less pure CNS action ensures it doesn't cause unwanted peripheral sympathetic stimulation.
Unfortunately the lay public is currently ill-served, a few shining exceptions aside, by the professionals. A condition of ignorance and dependence is actively fostered where it isn't just connived at in the wider population. So there's often relatively little point in advising anyone contemplating acting on DMF's book to consult their physician first. For it's likely their physician won't want to know, or want them to know, in the first instance.
As traditional forms of censorship, news-management and governmental information-control break down, however, and the Net insinuates itself into ever more areas of daily life, more and more people are stumbling upon - initially - and then exploring, the variety of drugs and combination therapies which leading-edge pharmaceutical research puts on offer. They are increasingly doing so as customers, and not as patronisingly labelled role-bound "patients". Those outside the charmed circle have previously been cast in the obligatory role of humble supplicants. The more jaundiced or libertarian among the excluded may have felt themselves at the mercy of prescription-wielding, or -withholding, agents of one arm of the licensed drug cartels. So when the control of the cartels and their agents falters, there is an especially urgent need for incisive and high-quality information to be made readily accessible. Do DMF fulfil it?
Smart Drugs 2 lays itself wide open to criticism; but then it takes on an impossible task. In the perennial trade-off between accessibility and scholarly rigour, compromises are made on both sides. Ritual disclaimers aside, DMF's tone can at times seem too uncritically gung-ho. Their drug-profiles and cited studies don't always give due weight to the variations in sample size and the quality of controls. Nor do they highlight the uncertain calibre of the scholarly journals in which some of the most interesting results are published. DMFs inclusion of anecdote-studded personal testimonials is almost calculated to inflame medical orthodoxy. Moreover it should be stressed that the scientific gold-standard of large, placebo-controlled, double-blind cross-over prospective trials are still quite rare in this field as a whole.
Looking ahead, this century's mood-boosting, intellect-sharpening, empathy-enhancing and personality-enriching drugs are themselves likely to prove only stopgaps. This is because invincible, life-long happiness and supergenius intellect may one day be genetically pre-programmed and possibly ubiquitous in our transhuman successors. Taking drugs to repair Nature's deficiencies may eventually become redundant. Memory- and intelligence-boosting gene therapies are already imminent. But in repairing the deficiencies of an educational system geared to producing dysthymic pharmacological illiterates, Smart Drugs 1 and 2 offers a warmly welcome start.
Refs and further reading
HedWeb Future Opioids BLTC Research Superhappiness? Utopian Surgery? Social Media 2015 Nutritional Medicine Wirehead Hedonism The Good Drug Guide The Abolitionist Project Reproductive Revolution Critique Of Brave New World MDMA: Utopian Pharmacology Nootropics/Smart Drugs: Sources The Biointelligence Explosion (2013) Male intelligence vs female intelligence Humans and AI: Co-evolution, Fusion or Replacement? (2013) e-mail info@nootropics.com
Link:
- Curious About Brain Optimization? Thesis Nootropics May Be Your In - The Edge - April 20th, 2024 [April 20th, 2024]
- Do nootropics and prebiotics actually do anything? Here's what the experts say - New York Post - April 20th, 2024 [April 20th, 2024]
- This coffee is amazing rave fans of London Nootropics Zen blend now 15% off... - The Sun - April 20th, 2024 [April 20th, 2024]
- What science reveals about adaptogens, probiotics, nootropics and CBD in rising functional drink trends - The Northlines - April 20th, 2024 [April 20th, 2024]
- A Forty-Something's Guide to the Best Brain Boosting Nootropics - Psychedelic Spotlight - October 29th, 2023 [October 29th, 2023]
- Unlocking brain health: The nootropic revolution - Smartbrief - October 29th, 2023 [October 29th, 2023]
- Customer Review: How I Dropped Two Pants Sizes With Inno Supps ... - Muscle & Fitness - October 29th, 2023 [October 29th, 2023]
- One research firm thinks Mississippi is a lot smarter than everyone ... - Darkhorse Press - October 29th, 2023 [October 29th, 2023]
- Assistance from AI: Virginian students struggle the most in the U.S. ... - Augusta Free Press - October 29th, 2023 [October 29th, 2023]
- Building better cognitive health supplements with smart formulations - Natural Products Insider - May 18th, 2023 [May 18th, 2023]
- Podiatry Treatment Market: Forthcoming Developments and ... - Cottonwood Holladay Journal - May 18th, 2023 [May 18th, 2023]
- That movie where Russell Crowe plays an exorcist might have ... - PC Gamer - May 18th, 2023 [May 18th, 2023]
- We tried the new soft drink called 'g-spot' by Gillian Anderson - Metro.co.uk - May 18th, 2023 [May 18th, 2023]
- Brain Health Supplements Market New Pathways for Research and Innovation are Being Opened by Trends ,Growth 20 - openPR - May 18th, 2023 [May 18th, 2023]
- Aussie nootropics start-up, Yootropics, eyes opportunities in healthy ... - NutraIngredients-Asia - May 2nd, 2023 [May 2nd, 2023]
- Nootropics Market Opportunities, Share, Growth and Competitive Analysis and Forecast 2029 - openPR - May 2nd, 2023 [May 2nd, 2023]
- SmartProtein Rebrands As Nutriv With Expanded Vision On ... - Digital Journal - May 2nd, 2023 [May 2nd, 2023]
- The Industry-Loved Supplement That Can Boost Brain Power - SheerLuxe - May 2nd, 2023 [May 2nd, 2023]
- Filler Bite Reaches 100% Funding Goal in Less Than 2 Days on ... - Digital Journal - May 2nd, 2023 [May 2nd, 2023]
- Social Shrooms Have Inspired The Next Wave Of Sober Curiosity - mindbodygreen - May 2nd, 2023 [May 2nd, 2023]
- The 12 Best Nootropics 2022: Top Smart Drugs and Brain Supplements - February 5th, 2023 [February 5th, 2023]
- The 10 Best Nootropic Supplements to Boost Brain Power - Healthline - February 5th, 2023 [February 5th, 2023]
- 8 Natural Nootropics To Improve Intelligence, Memory, And... - Biostrap - December 28th, 2022 [December 28th, 2022]
- London Nootropics adaptogenic coffee has all the perks without the crash - The Independent - October 19th, 2022 [October 19th, 2022]
- Keeping Your Brain In Shape Is Equally Important And Here's How To Do It - Seen in the City - October 19th, 2022 [October 19th, 2022]
- The keto diet and mental health: how closely should the food industry watch this trend? - FoodNavigator.com - October 19th, 2022 [October 19th, 2022]
- Nootropics revolution - patentability in the UK and EU - Lexology - October 13th, 2022 [October 13th, 2022]
- 'Sober' drinks are popular: Why? Are they a good alcohol alternative? - USA TODAY - October 13th, 2022 [October 13th, 2022]
- Almost Half Of US Adults Face Stress - This Company Believes Its Wearable Tech Is The Answer - Benzinga - October 13th, 2022 [October 13th, 2022]
- Focus On Functional Foods: 22 October | Feature Synopsis - The Grocer - September 22nd, 2022 [September 22nd, 2022]
- Nootropics That Actually Might Work, Say Experts Eat This Not That - Eat This, Not That - September 11th, 2022 [September 11th, 2022]
- The Nootropic Supplement This Former Gymnast Swears By For All-Day Energy - mindbodygreen - August 15th, 2022 [August 15th, 2022]
- Best Weight Loss Pills That Actually Work - Outlook India - August 2nd, 2022 [August 2nd, 2022]
- NooCube Reviews: Does It Work? - The Daily World - July 29th, 2022 [July 29th, 2022]
- Global Nootropics Market Report 2022: Market is Expected to Grow to $6.61 Billion in 2026 at a CAGR of 13 - Benzinga - July 29th, 2022 [July 29th, 2022]
- This Week's New Beverages: Black Adam-Themed Energy Drinks, Non-Alcoholic Aperitivos and Psychedelic Microdoses - BevNET.com - July 29th, 2022 [July 29th, 2022]
- The Terminal List season 1, episode 5 recap "Disruption" - Ready Steady Cut - July 4th, 2022 [July 4th, 2022]
- Improve Your Performance and Neurogenesis With These Five Easy Tips - Sporteluxe - July 4th, 2022 [July 4th, 2022]
- Supporting Brain Health with Foods, Beverages, and Supplements - WholeFoods Magazine - July 4th, 2022 [July 4th, 2022]
- Kin Euphorics Expands With a Mood-Boosting Ros, and Other News - Surface Magazine - May 21st, 2022 [May 21st, 2022]
- Alkalife pH Booster Drops Rated #1 for the Second Year in a Row - Digital Journal - May 11th, 2022 [May 11th, 2022]
- Reality goes beyond fiction. This cryptocurrency can change the future of businesses - Yahoo Finance UK - May 11th, 2022 [May 11th, 2022]
- Nootropics Market by Manufacturers, Types, Regions and Application Research Report Forecast to 2028 Queen Anne and Mangolia News - Queen Anne and... - May 7th, 2022 [May 7th, 2022]
- More than human: What is biohacking? - Daily Maverick - May 7th, 2022 [May 7th, 2022]
- Healthy Extracts First Major Brand Influencer Launches New Line of Natural Health and Fitness Formulations on WhitneyJohns.com - Yahoo Finance - May 7th, 2022 [May 7th, 2022]
- Best Brain Supplements, Nootropics and Memory Pills - NDTV - April 9th, 2022 [April 9th, 2022]
- These New Drinks Are Taking Over Your Grocery Store's Alcohol Aisle Eat This Not That - Eat This, Not That - April 9th, 2022 [April 9th, 2022]
- Best Nootropics - Buy the Top Brain Booster Nootropic Supplements - Okanogan Valley Gazette Tribune - March 13th, 2022 [March 13th, 2022]
- 4 Best Nootropics in 2022: Top 4 Brain Supplements and Smart Drugs - The Hindu - March 8th, 2022 [March 8th, 2022]
- HOP WTR Leans Into the Positive Power of "No" With "Up To No Good" Campaign - BevNET.com - March 8th, 2022 [March 8th, 2022]
- In the Aisle: Non-alcoholic beverages go beyond zero proof - New Hope Network - March 8th, 2022 [March 8th, 2022]
- Smart Pill Technologies Market 2022 Size, Share, Growth, Trends, COVID-19 Impact Analysis, and Forecasts to 2028 - Digital Journal - February 21st, 2022 [February 21st, 2022]
- Read This Before You Buy Nootropics. What are the Best Nootropics? Thesis Customized Nootropics Review: The Most Effective Brain Supplements. -... - February 11th, 2022 [February 11th, 2022]
- Here's Why the Jonas Brothers Invested in a Vegan Snack Company - VegOut Magazine - February 11th, 2022 [February 11th, 2022]
- Global Connected Healthcare Market Growing Demand, Future Trends, Competitive Regions and Forecast 2021 to 2027 The Grundy Register - The Grundy... - February 9th, 2022 [February 9th, 2022]
- Sometimes you feel like a nut: almonds in the mood food movement - FoodNavigator-USA.com - February 9th, 2022 [February 9th, 2022]
- Global Nootropics Market Is Set To Reach $5959 Million By 2024 | Exclusive Report by Esticast Research The Grundy Register - The Grundy Register - February 7th, 2022 [February 7th, 2022]
- Hop Wtr Heads Into 2022 With Zest: Introducing Lime - Brewbound.com - February 7th, 2022 [February 7th, 2022]
- Brain health: how to age-proof your brain and stay sharp - Get The Gloss - February 7th, 2022 [February 7th, 2022]
- Best Nootropics (2022) Review Top-Rated Nootropic Supplements - Kirkland Reporter - January 30th, 2022 [January 30th, 2022]
- You Wont Believe What Bella Hadid Just Revealed About Her DrinkingWere So Surprised! - SheFinds - January 30th, 2022 [January 30th, 2022]
- Beverages With Benefits: Do They Really Work? OR Are Beauty Drinks Too Good to Be True? - The New York Times - January 21st, 2022 [January 21st, 2022]
- 3 Key Supplement and Wellness Trends to Watch in 2022 - Green Entrepreneur - January 21st, 2022 [January 21st, 2022]
- Global Smart Drugs Market 2021 Valuable Growth Prospects and Upcoming Trends till 2027 Discovery Sports Media - Discovery Sports Media - January 21st, 2022 [January 21st, 2022]
- How To Clear Your Frazzled Brain and Regain Your Focus - Intelligent Living - January 21st, 2022 [January 21st, 2022]
- LifeVantage to Announce Second Quarter Fiscal Year 2022 Results on February 1, 2022 - Stockhouse - January 21st, 2022 [January 21st, 2022]
- The Different Types Of Supplements And Their Main Benefits - Toys Matrix - January 17th, 2022 [January 17th, 2022]
- This Energy Drink Uses Nootropics To Give Your Brain The Boost It Needs - TMZ - January 9th, 2022 [January 9th, 2022]
- Keep yourself healthy this winter with up to 30% off supplements from Amazon - SFGate - January 9th, 2022 [January 9th, 2022]
- Methylene Blue Nootropics Expert - December 7th, 2021 [December 7th, 2021]
- Can Mushrooms Help in Managing Alzheimer's Disease? Here's What we Know - India.com - December 7th, 2021 [December 7th, 2021]
- These 3 Trends Will Impact the Future of Snacking - NACS Online - December 7th, 2021 [December 7th, 2021]
- Drinking To The Future: Heres How Bella Hadid And Jen Batchelor Are Leading The Age Of Sober Curiosity With Kin Euphorics - Forbes - December 7th, 2021 [December 7th, 2021]
- Nootropics Expert | The Authority on Nootropic Supplements - December 3rd, 2021 [December 3rd, 2021]
- IFF Health Advances in Brain Health Innovation with New Research that Demonstrates Benefits on Cognitive Performance - PR Web - December 3rd, 2021 [December 3rd, 2021]
- Mondelez executive expects three issues to impact snacks category - Food Business News - December 3rd, 2021 [December 3rd, 2021]
- The Complete Introduction To Nootropics, From Beginner To ... - November 28th, 2021 [November 28th, 2021]
- Buy Piracetam Powder | Nootropics Depot - November 28th, 2021 [November 28th, 2021]
- RTD beverages broaden appeal with functional ingredients - Natural Products INSIDER - November 19th, 2021 [November 19th, 2021]
- Buy Piracetam Capsules 800mg | Nootropics Depot - November 15th, 2021 [November 15th, 2021]